Precipio inc.

Precipio, Inc. 4 Science Park . New Haven, Connecticut 06511 (203) 787-7888 (Name, address, including zip code and telephone number, including area code, of agent for service) Copies to: Thomas A. Rose . Sichenzia Ross Ference LLP. 1185 Avenue of the Americas, 37th Floor. New York, NY 10036Precipio, Inc. announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share. Keith brings over 30 years of executive experience in various healthcare organizations, including his recent position as Vice President of Marketing at Fresenius Kabi.Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective. If any of the securities being registePrecipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and ...

Exhibit 99.1 . Precipio Announces Second Quarter Shareholder Update Call . Conference Call to be held on Monday, August 15 th, 2022 at 5:00 PM EST. NEW HAVEN, CT, Globenewswire – (August 8 th, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2022 shareholder update call on Monday, …On March 16 Precipio, Inc. (the “Company”) issued a press release in connection with the company’s completion of a transaction relating to Oncometrix Hematopathology division.The press release is furnished as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is …

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.About Precipio. Precipio Inc. is a healthcare company focused on cancer diagnostics. The Company’s mission is to address the pervasive problem of cancer misdiagnosis by developing products to ...

Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizations. NEW HAVEN, CT – (Globenewswire) – (June 13 th, 2022) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market ...Precipio, Inc. (NASDAQ:PRPO) posted its quarterly earnings data on Thursday, August, 23rd. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $38.60 by $41.60. The biotechnology company had revenue of $0.82 million for the quarter. Precipio had a …As previously reported on October 13, 2016, Transgenomic, Inc. (the “Company”), New Haven Labs Inc., a wholly-owned subsidiary of the Company, and Precipio Diagnostics, LLC (“Precipio”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Precipio will become a wholly-owned subsidiary of the Company (the …Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective. If any of the securities being registe

FORM 8-K. CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2021 PRECIPIO, INC.

Precipio’s R&D team estimates a development time of under 4 months for this assay, and a cost of less than $50,000, an unprecedented speed and development cost in this industry.

Invisible Fence Inc. is a leading provider of innovative pet containment and lifestyle solutions. With over 40 years of experience, Invisible Fence Inc. has developed products that are designed to keep pets safe and secure in their own yard...Exhibit 99.1 . Precipio Announces Second Quarter Shareholder Update Call . Conference Call to be held on Monday, August 15 th, 2022 at 5:00 PM EST. NEW HAVEN, CT, Globenewswire – (August 8 th, 2022) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2022 shareholder update call on Monday, …On November 2, 2017, Precipio, Inc. (the “Company”) entered into a Placement Agency Agreement (the “Placement Agreement”) with Aegis Capital Corp. for the sale on a reasonable best efforts basis of 2,748 units, each consisting of one share of the Company’s Series C Convertible Preferred Stock, par value $0.01 per share (the “Preferred Stock”), …Precipio’s Board oversees the CEO and other senior management in the competent and ethical operation of Precipio, Inc. on a day-to-day basis and assures that the long-term interests of stockholders are being served.Precipio, Inc. announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share. Keith brings over 30 years of executive experience in various healthcare organizations, including his recent position as Vice President of Marketing at Fresenius Kabi.

NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from ...Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScree...Precipio is a cancer diagnostics company. Gained 20.04% to close Tuesday's (Apr.30) trading at $6.05. News: The Company has signed a services contract with a health care management group serving ...Precipio, Inc. Oct 2021 - Present2 years. New Haven, Connecticut, United States. Ensure every client receives case reports within the expected turn around time by overseeing the status and ...NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from ...

Follow. NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4 ...Accurate Blood Cancer Testing with Omnia TM. Even with advances in oncology diagnostics, blood cancers are misdiagnosed or misclassified at an alarming rate. At Precipio, we are revolutionizing hematopathology diagnostics through our innovative Omnia methodology, ensuring more accurate and reliable results for every sample we receive.

On January 13, 2020 Precipio, Inc. (the “Company”) issued a press release.As noted in the press release, management will host an update conference call where management will provide a strategic business update and will respond to questions submitted in advance via email initiatives on Monday 20, 2020, at 5:00pm Eastern Time.Item 8.01. Other Events. On May 23, 2019, Precipio, Inc. (the “Company”) announced that Ilan Danieli, its Chief Executive Officer, adopted a stock trading plan in accordance with Rule 10b5-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), to purchase shares of the Company’s common stock (the “Plan”).Safari is a popular web browser developed by Apple Inc. Known for its sleek design and seamless user experience, Safari has grown to become one of the most widely used browsers across various devices.After the upgrade, the solo analyst covering Precipio is now predicting revenues of US$15m in 2023. If met, this would reflect a substantial 39% improvement in sales compared to the last 12 months ...NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read ...Jan 13, 2020 · NEW HAVEN, Conn., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that on Monday, January 20th at 5pm it will conduct a shareholder ... Precipio’s platform delivers superior diagnostic accuracy through specialized expertise and cutting edge technology. We are a laboratory focused on delivering superior hematology diagnostic services to physicians and their patients to ensure they receive accurate results.

PRECIPIO, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-36439 (Commission File Number) 91-1789357 (IRS Employer Identification No.) 4 Science Park, New Haven, CT 06511 (Address of principal executive offices) (Zip Code)

Precipio, Inc. (NASDAQ:NASDAQ:PRPO) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ETCompany ParticipantsIlan Danieli - CEOConference Call...

NEW HAVEN, Conn., June 07, 2023 -- Specialty cancer diagnostics company Precipio, Inc. , announces that several operational improvement initiatives which commenced at the start of the year have...Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.Mogo Inc. (NASDAQ:MOGO) Q3 2023 Earnings Call Transcript November 9, 2023 Mogo Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.12. Operator: Good afternoon, ladies and gentlemen. And welcome to the Mogo Third Quarter 2023 Earnings Conference Call [Operator Instructions]. This call is being recorded on …Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScree...Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses.A. Zaki Sabet has been with Precipio since co-founding the company in 2011 and currently serves as the Chief Operating Officer. He holds over 12 years of experience in laboratory management spanning all fields of reference laboratory operations primarily focusing on cancer diagnostics. Prior to Precipio, Zaki has served as a consultant with the ... Precipio, Inc. Aug 2022 - Present 1 year 4 months Precipio’s Products Division, develops, produces and sells proprietary diagnostic products to laboratories.Conference Call to be held on Monday, April 3rd, 2023 at 5:00 PM ETNEW HAVEN, Conn., March 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be ...JLG Industries, Inc. is a global company that designs and manufacturers access equipment. Learn how to find JLG parts online. Since 1969, JLG has delivered powerful, versatile equipment as well as training and service.PRECIPIO, INC. (Exact Name of Registrant as Specified in Its Charter . Delaware (State of Incorporation) 001-36439 (Commission File Number) 91-1789357 (I.R.S. Employer Identification No.) 4 Science Park, New Haven, CT 06511 (Address of principal executive offices) (Zip Code)Jun 13, 2023 · Precipio’s R&D team estimates a development time of under 4 months for this assay, and a cost of less than $50,000, an unprecedented speed and development cost in this industry. C/O PRECIPIO, INC. 4 SCIENCE PARK (Street) NEW HAVEN: CT: 06511 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol Precipio, Inc. [ PRPO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: 10% Owner: X: Officer (give title below)

Jan 28, 2021 · Following the receipt of FDA EUA by Nirmidas, Precipio begins market roll out to POC. January 28, 2021 09:30 ET | Source: Precipio, Inc. Includes base and annual incentives. $67 k. $74.5 k. $82 k. $68,102. $82,621. $74,488. These charts show the average base salary (core compensation), as well as the average total cash compensation for the job of Civil Engineer I in Atlanta, GA. The base salary for Civil Engineer I ranges from $67,465 to $81,045 with the average base salary of ...Accurate Blood Cancer Testing with Omnia TM. Even with advances in oncology diagnostics, blood cancers are misdiagnosed or misclassified at an alarming rate. At Precipio, we are revolutionizing hematopathology diagnostics through our innovative Omnia methodology, ensuring more accurate and reliable results for every sample we receive. Precipio, Inc. was founded in 2011 and has since established itself as a key player in the healthcare industry. The company offers a wide range of diagnostic and treatment solutions, with a primary focus on cancer. As of 2023, Precipio, Inc. has reported a substantial increase in sales, indicating a growing demand for its products and services.Instagram:https://instagram. trading computerfsrstockwhat platforms can you day trade onflorida fine cars orlando Precipio, Inc. (PRPO) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 7.00 -0.22 (-3.05%) At close: 03:20PM EST 6.74 +0.01 (+0.15%) After hours: 04:09PM EST Summary Company... vistaa1964 half dollar how much is it worth Exhibit 99.1 . Precipio Announces Q2-2023 Shareholder Update Call. Conference Call to be held on August 17, 2023 at 5:00 PM EST. NEW HAVEN, CT, (August 10 th, 2023) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17 th at 5:00 PM ET. The call will include … transfer 529 HemeScreen ® Reagents Product Information. HemeScreen is a Research Use Only (RUO) proprietary mutation detection technology that is rapid, cost-effective, and easy-to-use. HemeScreen reagents can be run on most RT-PCR instruments and leverage efficient HRM (High Resolution Melt) technology to identify gene mutations and other variants at low …ITEM 1 (a) NAME OF ISSUER: Precipio, Inc. ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 4 Science Park, New Haven, CT 06511 . ITEM 2 (a) NAME OF PERSON FILING: Leviston Resources LLC . ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: 708 Third Avenue, 6 th …